Showing 1,801 - 1,817 results of 1,817 for search '(( significant ((larger decrease) OR (largest decrease)) ) OR ( significant event decrease ))', query time: 0.49s Refine Results
  1. 1801

    Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  2. 1802

    Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  3. 1803

    Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  4. 1804

    Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”
  5. 1805

    Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”
  6. 1806

    Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  7. 1807

    Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”
  8. 1808

    Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”
  9. 1809

    Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  10. 1810

    Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  11. 1811

    Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  12. 1812

    Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
  13. 1813

    Supplementary file 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

    Published 2025
    “…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I<sup>2</sup> = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I<sup>2</sup> = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I<sup>2</sup> = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I<sup>2</sup> = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I<sup>2</sup> = 86%). …”
  14. 1814

    Supplementary file 2_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

    Published 2025
    “…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I<sup>2</sup> = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I<sup>2</sup> = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I<sup>2</sup> = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I<sup>2</sup> = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I<sup>2</sup> = 86%). …”
  15. 1815

    Data Sheet 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a systematic... by Yajing Li (1394572)

    Published 2025
    “…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I<sup>2</sup> = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I<sup>2</sup> = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I<sup>2</sup> = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I<sup>2</sup> = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I<sup>2</sup> = 86%). …”
  16. 1816

    Image 2_Standardized aqueous extract of Abutilon theophrasti Medic. ameliorates oxidative stress and inflammatory responses against hydrochloric acid/ethanol-induced gastric ulcer... by Hui Guo (110581)

    Published 2025
    “…Overall, the presented results greatly supported and validated the essential inflammation and oxidation events implicated in the mechanistic investigation using bioinformatics.…”
  17. 1817

    Image 1_Standardized aqueous extract of Abutilon theophrasti Medic. ameliorates oxidative stress and inflammatory responses against hydrochloric acid/ethanol-induced gastric ulcer... by Hui Guo (110581)

    Published 2025
    “…Overall, the presented results greatly supported and validated the essential inflammation and oxidation events implicated in the mechanistic investigation using bioinformatics.…”